Coloplast A/S

CPSE:COLO B Stock Report

Market Cap: DKK 135.7b

Coloplast Valuation

Is COLO B undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

6/6

Valuation Score 6/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of COLO B when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
DKK 1.00k
Fair Value
39.9% undervalued intrinsic discount
18
Number of Analysts

Below Fair Value: COLO B (DKK601.6) is trading below our estimate of fair value (DKK1000.99)

Significantly Below Fair Value: COLO B is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for COLO B?

Key metric: As COLO B is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for COLO B. This is calculated by dividing COLO B's market cap by their current earnings.
What is COLO B's PE Ratio?
PE Ratio29.8x
EarningsDKK 4.54b
Market CapDKK 135.73b

Price to Earnings Ratio vs Peers

How does COLO B's PE Ratio compare to its peers?

The above table shows the PE ratio for COLO B vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average39.1x
DEMANT Demant
19.5x9.54%DKK 56.3b
AMBU B Ambu
71.6x25.24%DKK 26.7b
EMBLA Embla Medical hf
31.1x11.20%DKK 14.3b
COO Cooper Companies
34.3x17.46%US$14.2b
COLO B Coloplast
29.8x16.27%DKK 135.7b

Price-To-Earnings vs Peers: COLO B is good value based on its Price-To-Earnings Ratio (29.8x) compared to the peer average (39.1x).

Price to Earnings Ratio vs Industry

How does COLO B's PE Ratio compare vs other companies in the European Medical Equipment Industry?

4 CompaniesPrice / EarningsEstimated GrowthMarket Cap
COLO B 29.8xIndustry Avg. 32.1xNo. of Companies9PE020406080100+
4 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: COLO B is good value based on its Price-To-Earnings Ratio (29.8x) compared to the European Medical Equipment industry average (32.1x).

Price to Earnings Ratio vs Fair Ratio

What is COLO B's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

COLO B PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio29.8x
Fair PE Ratio37.3x

Price-To-Earnings vs Fair Ratio: COLO B is good value based on its Price-To-Earnings Ratio (29.8x) compared to the estimated Fair Price-To-Earnings Ratio (37.3x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst COLO B forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentDKK 601.60
DKK 743.44
+23.58%
10.89%DKK 962.00DKK 600.00n/a18
Jun ’26DKK 635.60
DKK 751.95
+18.31%
10.83%DKK 962.00DKK 640.00n/a19
May ’26DKK 705.40
DKK 896.20
+27.05%
11.46%DKK 1,050.00DKK 694.00n/a20
Apr ’26DKK 726.40
DKK 910.71
+25.37%
10.85%DKK 1,050.00DKK 700.00n/a21
Mar ’26DKK 764.00
DKK 909.76
+19.08%
10.85%DKK 1,050.00DKK 700.00n/a21
Feb ’26DKK 830.00
DKK 911.43
+9.81%
10.74%DKK 1,030.00DKK 700.00n/a21
Jan ’26DKK 786.20
DKK 924.43
+17.58%
9.41%DKK 1,030.00DKK 700.00n/a21
Dec ’25DKK 889.40
DKK 924.67
+3.97%
9.44%DKK 1,030.00DKK 700.00n/a21
Nov ’25DKK 871.80
DKK 913.33
+4.76%
11.03%DKK 1,050.00DKK 700.00n/a21
Oct ’25DKK 876.40
DKK 913.60
+4.24%
11.03%DKK 1,060.00DKK 700.00n/a20
Sep ’25DKK 920.20
DKK 911.35
-0.96%
11.26%DKK 1,060.00DKK 700.00n/a20
Aug ’25DKK 896.00
DKK 905.90
+1.10%
10.97%DKK 1,060.00DKK 710.00n/a20
Jul ’25DKK 832.40
DKK 895.40
+7.57%
10.53%DKK 1,060.00DKK 710.00n/a20
Jun ’25DKK 824.80
DKK 909.89
+10.32%
10.22%DKK 1,060.00DKK 710.00DKK 635.6019
May ’25DKK 836.40
DKK 917.05
+9.64%
10.86%DKK 1,060.00DKK 700.00DKK 705.4019
Apr ’25DKK 932.40
DKK 897.32
-3.76%
10.26%DKK 1,060.00DKK 700.00DKK 726.4019
Mar ’25DKK 917.00
DKK 871.79
-4.93%
10.07%DKK 1,000.00DKK 700.00DKK 764.0019
Feb ’25DKK 799.80
DKK 823.74
+2.99%
9.81%DKK 962.00DKK 631.00DKK 830.0019
Jan ’25DKK 772.00
DKK 816.56
+5.77%
10.25%DKK 962.00DKK 631.00DKK 786.2018
Dec ’24DKK 788.60
DKK 817.67
+3.69%
10.11%DKK 962.00DKK 631.00DKK 889.4018
Nov ’24DKK 750.20
DKK 848.78
+13.14%
9.20%DKK 980.00DKK 686.00DKK 871.8018
Oct ’24DKK 747.60
DKK 865.24
+15.74%
9.89%DKK 1,000.00DKK 686.00DKK 876.4017
Sep ’24DKK 788.00
DKK 907.53
+15.17%
10.13%DKK 1,070.00DKK 720.00DKK 920.2015
Aug ’24DKK 826.60
DKK 928.88
+12.37%
9.93%DKK 1,070.00DKK 720.00DKK 896.0016
Jul ’24DKK 853.20
DKK 915.44
+7.29%
11.05%DKK 1,070.00DKK 690.00DKK 832.4016
Jun ’24DKK 874.80
DKK 915.44
+4.65%
11.05%DKK 1,070.00DKK 690.00DKK 824.8016
AnalystConsensusTarget
Consensus Narrative from 18 Analysts
DKK 743.44
Fair Value
19.1% undervalued intrinsic discount
18
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/06/30 19:43
End of Day Share Price 2025/06/30 00:00
Earnings2025/03/31
Annual Earnings2024/09/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Coloplast A/S is covered by 51 analysts. 19 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullABG Sundal Collier
Hassan Al-WakeelBarclays
Robert BateBarclays